First Rituxan biosimilar Truxima set to make its debut in US
Humira tops list of drugs with unwarranted US price hikes
Roche raises 2019 outlook, shrugging off biosimilar threat
Celgene bags FDA okay for Revlimid combo in lymphoma
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.
Genentech’s Rituxan approved for rare skin disease